Rohit Singh, MD

Medical Oncologist, Asst Professor @UVMMedCenter; alum editorial fellow@JCO_ASCO; member @ASCOTECAG. Immuno-Oncology, thoracic & cutaneous Oncology

[Rohit Singh, MD @RohitBanwar]

Grateful to join the ASCO 2026 Featured Voices cohort. Excited to engage with the oncology community and highlight impactful science, clinical insights, mentorship, and advocacy throughout #ASCO26 @UVMDeptMed @UVMcancercenter @ASCO

[ASCO @ASCO]

We’re pleased to announce our Featured Voices for #ASCO26! Get their expert insights into the science & ed sessions, what they view as practice changing & how to bring the learning into the clinic. Be a part of the conversation using the meeting hashtag. https://t.co/nUt3OwsT6x

[Rohit Singh, MD @RohitBanwar]

@KalantriShreyas @ASCO @AACR @ConquerCancerFd @JCO_ASCO @HemOncFellows @IMG_Oncologists @oncodaily @OncLive Many congratulations Shreyas😊

[Rohit Singh, MD @RohitBanwar]

@triparnasen @OSUCCC_James @OSUWexMed @OhioStateMedOnc Many Congratulations 😊

[Rohit Singh, MD @RohitBanwar]

@COlazagasti @SylvesterCancer @GlopesMd @DrTracyECrane @NarjustFlorezMD @Latinamd @DrFrankJPenedo @KobetzErin @LaurenGroner @DrSDNimer Congratulations 😊

[Ashley Love Sumrall, MD, FACP, FASCO @AshleySumrallMD]

@RepEllzey & @MarioDB are the latest 2 reps to cosponsor @MikeKellyPA ‘s bill: #HR3514 - seniors’ act. Thx!! Who will be the FINAL 2 cosponsors to kick this bill out of cmte? Let’s 👏🏻get 👏🏻it 👏🏻passed!! @asco #advocacy @ACSCAN https://t.co/om0vDwkqQJ

[Ashley Love Sumrall, MD, FACP, FASCO @AshleySumrallMD]

🚨🚨We officially have 288 cosponsors on Seniors’ Act
#HR3514
- STOP faxes
- Increase transparency
With 290, we can force a supermajority & the bill can move to the calendar. TWO more cosponsors…Let’s go! @asco #asco26 #advocacy
👉🏻👉🏻👉🏻

[Rohit Singh, MD @RohitBanwar]

@LauraAlderMD Many Congratulations; teaching is indeed one of the greatest joys😊🎉

[Rohit Singh, MD @RohitBanwar]

Fascinating work. The most compelling aspect may not be the 14-protein signature itself, but the concept that lung carcinogenesis can potentially be intercepted during an inflammatory “tumor-promoting” state years before radiographic diagnosis.

At the same time, important to remember this is a risk-enrichment biomarker, not destiny; most patients with a high signature still never developed lung cancer. The key next step will be prospective validation: can targeting the IL-1β/inflammatory axis in biomarker-selected high-risk populations truly prevent cancer while maintaining an acceptable risk/benefit profile? @EricTopol @nytimes @ASCO

[Rohit Singh, MD @RohitBanwar]

@drshieldsmd @ASCO @ASCOPost @ConquerCancerFd @IUCancerCenter @SclcSMASHERS @LUNGevity @LaurenByersMD @FordePatrick @g_mountzios @drshieldsmd, it was a very informative and clinically applicable presentation and discussion. Thank you😊🙏🏼

[Rohit Singh, MD @RohitBanwar]

@royaryam @NazliDizman @ASCO @ASCOTECAG @IMG_Oncologists @OncoAlert @montypal @SPremji7866 @ja_ocejo @OncBrothers @realbowtiedoc @Noha_Soror @ASridharMD @AnaVManana @AmandaNizamMD @neerajaiims @FionnualaCrowle @IvyLorena_Md Grateful to have you as my friend 😊

[Rohit Singh, MD @RohitBanwar]

@OncoAlert I appreciate the access to all the incredible data presented in such a clear and concise way. It’s invaluable for staying informed and ahead of the curve. Thank you 🙏🏼

[Rohit Singh, MD @RohitBanwar]

Science, collaboration, mentorship, and friendships; that's what's makes #ASCO26 so memorable.
(Still can’t believe the cover cameo 😅). Will get it framed 🤩

[Nazli Dizman @NazliDizman]

😎Yes, we found him!

The unofficial face of #ASCO26. Our super awesome, uber cool and incredibly kind friend @RohitBanwar made it to the cover! 🥳👏

@ASCO @ASCOTECAG @IMG_Oncologists @OncoAlert @montypal @SPremji7866 @IMG_Oncologists @ja_ocejo @OncBrothers @realbowtiedoc @DVAraujoMD @DrBarbiOnc @LauraEsfeller @FunchainMD @YGaritaonaindia @jgong15 @DrSAHaddad @iandresmeraz @SakditadMD @RamilaShilpakar @lungoncdoc @DrYukselUrun @yekeduz_emre

[Rohit Singh, MD @RohitBanwar]

@NazliDizman @montypal @ASCO @ASCOTECAG @IMG_Oncologists @OncoAlert @SPremji7866 @ja_ocejo @OncBrothers @realbowtiedoc @Noha_Soror @royaryam @ASridharMD @AnaVManana @AmandaNizamMD @neerajaiims @FionnualaCrowle @IvyLorena_Md Thank you so much Nazli @NazliDizman. That was a wonderful surprise; still not sure how I ended up on the cover😁. I think it's the @ASCOTECAG effect. Very grateful for the friendships, mentorship, and collaborations.

[Rami Manochakian MD, FASCO Cancer Education @RManochakian]

🔥🚨@OncoAlert Hot off the press.

Just presented @ASCO #ASCO26 by Dr.
@LaurenByersMD

⭐️ Results of phase 1 trial of:

❇️#ABBV706 (#SEZ6 #ADC) as #monotherapy & in combination with #Budigalimab (anti-PD1 Ab) in patients with relapsed/refractory #SmallCell #LungCancer (#SCLC).

For pts on Monotherapy:
✅#ORR: 52% (82% at 1.8 mg/kg in 2L)
✅#mOS: 11.3 m (14.3 at 1.8 mg/kg in 2L)

For pts on combination:
✅#ORR: 55%
✅#mOS: not reached

[Rami Manochakian MD, FASCO Cancer Education @RManochakian]

‼️‼️#Tarlatamab Keeps delivering.

🔥🚨@OncoAlert Hot off the press.
Just presented @ASCO #ASCO26 by Dr. @g_mountzios

⭐️#PostHoc Analysis Results of #Intracranial🧠#Efficacy of:

❇️#Tarlatamab 🆚 #Chemotherapy in #2nd line treatment for #SmallCell #LungCancer in the #DeLLphi304 Trial.

‼️‼️#Exciting & #Promising Results:

✅⬆️CNS #mPFS 6.5 vs 4.2 m (HR 0.40)
✅⬆️CNS #CR: 15% vs 5%
✅⬆️CNS shrinkage ≥30%: 56% vs 38%
✅⬆️#mOS in pts with #BrainMets:
13.9 vs 6.8 m

[Suresh S. Ramalingam, MD, FASCO @RamalingamMD]

The actual pCR rate is 34%- they conveniently left out 11 patients from the denominator. This is misleading reporting! @WinshipAtEmory #lcsm # ASCO2026.

[Nazli Dizman @NazliDizman]

Have you seen this? @ASCO @ASCOTECAG is breaking records this year! 🎉
👏Over 250 1-on-1 mentoring meetings, 90+ panelists, and 15 panels, roundtables, and networking events! Don't forget to check out the Trainee & Early-Career Lounge if you haven't already!

#ASCO26 @Na@NazliDizman @ASCOPres @AnnPartridgeMD @PTarantinoMD @BourlonMaite @HundalJasmin @Chris_PouliosMD @quantumonc @rohitbanwar @noha_soror @royaryam @heberolimus @IbrahimAzarOnc @Dr_Crazy94 @dominicandoc2 @OncoAlert @montypal @SPremji7866 @IMG_Oncologists @DrChoueiri @jrgralow @FionnualaCrowle @ja_ocejo @noha_soror @royaryam @OncoAlert @OncBrothers @crisbergerot @PauloBergerot @realbowtiedoc @DVAraujoMD @DrBarbiOnc @LauraEsfeller @FunchainMD @YGaritaonaindia @jgong15 @DrSAHaddad @GIMedOnc @iandresmeraz @SakditadMD @RamilaShilpakar @RohitBanwar @lungoncdoc @BHuffmanMD @AnaVManana @AmandaNizamMD

[Alfredo Addeo MD @Alfdoc2]

#ASCO26 #TRITON @FSkoulidis
I’m struggling to understand the value of highlighting secondary endpoints while the primary endpoint remains blinded.
The reported improvements in ORR and DoR for tremelimumab + durvalumab + chemotherapy versus pembrolizumab + chemotherapy are numerical rather than compelling, and small patient numbers. Without the 1ry endpoint, it is impossible to know whether these findings represent a meaningful clinical advance or simply noise. Let’s wait for the study to read out before drawing conclusions. #NSCLC #LCSM

[Rohit Singh, MD @RohitBanwar]

One of the conceptually innovative abstracts at #ASCO26:

ARCHER explored a prophylactic peptide vaccine (ALK-Vac) targeting common ALK resistance mutations before progression in ALK+ NSCLC patients benefiting from TKIs.

Key findings:
• 15 pts; most on frontline ALK TKIs
• No grade ≥3 TRAEs
• Vaccine specific T-cell responses in 71%
• Responses observed against G1202R, L1196M, D1203N, E1210K, and I1171 mutations
• Disease control rate: 93% at median 11.5 mo follow-up

What makes this especially intriguing is the strategy itself: proactively targeting predictable resistance biology in a minimal residual disease setting rather than waiting for resistant clones to dominate clinically.

Interestingly, one progressing patient developed KRAS G12D rather than an emergent ALK resistance mutation, raising provocative questions about whether immune pressure could potentially alter evolutionary resistance trajectories.

Very early data, small numbers, and no efficacy conclusions yet, but a fascinating “immune interception” framework that could eventually extend beyond ALK to other oncogene-driven NSCLC subsets.

#LCSM #LungCancer #ALK @asco @KimmelCancerCtr @vincentlamMD

[Rohit Singh, MD @RohitBanwar]

Targeted therapy for non-classical EGFR mutations at #ASCO26

Presented by Dr. Rotow from DFCI. Silevertinib (BDTX-1535) in treatment-naive NSCLC with non-classical EGFR mutations showed encouraging activity in a population where outcomes with standard EGFR TKIs are often inconsistent.

Key findings:
• 43 pts with 35 unique non-classical EGFR mutations
• ORR appears robust across mutation subsets
• CNS ORR: 86% (6/7)
• ctDNA clearance: 81%
• 6-mo PFS: 86% overall; 80% with CNS mets

Particularly interesting activity in PACC and compound EGFR mutations.

Toxicities were consistent with the EGFR TKI class, though dose reductions were common (77%). Encouragingly, most responders maintained or deepened responses after dose reduction.

Still early with short follow-up and small numbers, but this could become an important option for a genomically underserved EGFR population where we often extrapolate beyond available data.

#LCSM #LungCancer @ASCO @JuliaRotow

[OncoAlert @OncoAlert]

Day 1 of #ASCO26 delivered practice-changing data across #LungCancer #BladderCancer #KidneyCancer Captured by the @OncoAlert 🚨 Round Up

🔹 7-year CROWN update confirms unprecedented durability with lorlatinib in ALK+ NSCLC @TonyMok9
🔹 ADC + immunotherapy combination shows major frontline promise in NSCLC
🔹 Sunvozertinib emerges as a new first-line standard for EGFR exon20ins disease
🔹 EV-302 continues to redefine survival in metastatic urothelial carcinoma @tompowles1
🔹 ctDNA analyses from KEYNOTE-564 move us closer to precision adjuvant RCC care @DrChoueiri
Catch all the key studies and clinical insights in the latest OncoAlert ASCO 2026 Day 1 Roundup.
🎧 Listen now and stay ahead of the science.

#ASCO26
@StephenVLiu
@DrYukselUrun
@UOzkerim
@OncBrothers
@SakditadMD
@DrRishabhOnco
@M_Torasawa
@alanazi002
@HerediaOncologo
@aebchang
@RManochakian
@CParkMD
@RohitBanwar
@diegoadiazg
@tugbawitter
@DrMirallas
@johanpluvy
@GlopesMd
@josemarciofigu1
@HHorinouchi
@JordiRemon
@ManuelDomine
@SuyogCancer
@ilyassahinMD
@tompowles1
@DrChoueiri
@nataliagandur
@shilpaonc
@yekeduz_emre
@KalantriShreyas
@to_be_elizabeth
@zklaassen_md
@MarioBalsaMD
@WDKhatoun
@katy_beckermann
@iandresmeraz
@fuatbcr
@ADESAIONCMD
@docjavip